| Wissenschaftl. Titel | A Phase II, Open-label, Single Arm Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (PKC412) Combined With Standard Chemotherapy and as a Single Agent Post-consolidation Therapy in Children With Untreated FLT3-mutated AML |
| Erkrankung |
Haema:
AML:
Erstlinie
|
| Molekularer Marker |
FLT3 |
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (NIH) Weiterführende Informationen (EudraCT) |
erstellt 15.03.2023 Data entry III CCP
geändert 13.09.2023 Data entry II CCP